首页 > 最新文献

Journal of Endocrinological Investigation最新文献

英文 中文
Measurement of PDE5 concentration in human serum: proof-of-concept and validation of methodology in control and prostate cancer patients. 人体血清中 PDE5 浓度的测量:对照组和前列腺癌患者的概念验证和方法验证。
IF 5.4 2区 医学 Q1 Medicine Pub Date : 2024-10-01 DOI: 10.1007/s40618-024-02428-w
Giovanni Luca Gravina, Eugenia Guida, Maria Dri, Renato Massoud, Savino M Di Stasi, Giorgio Fucci, Andrea Sansone, Susanna Dolci, Emmanuele A Jannini

Purpose: We aimed to investigate if the type 5 phosphodiesterase (PDE5), an enzyme with cardinal biological functions in sexual and cardiovascular health, can be detected and quantited in human serum.

Methods: Blood samples were collected from control male and female subjects. PDE5 levels were measured by a specific ELISA kit. ROC curves weighted for age and serum levels of PSA (male subjects), or age (female subjects) were used to identify the predictive ability in the detection of PCa. Sensitivity, specificity, PPV and NPV values were determined for cut-off value determined during ROC curve analysis.

Results: 41 control male subjects, 18 control female subjects, and 55 consecutive subjects, of which 25 were affected by benign prostatic hypertrophy (BPH) and 30 with histologically confirmed prostate cancer (PCa), were studied. PDE5 serum levels were detectable in all subjects (range: 5 to 65 ng/ml). Analysis by MANCOVA identified a significant difference in serum PDE5 between control subjects or hyperplasia patients and PCa patients. Marginal means of serum PDE5 concentrations showed a significant difference (p < 0.001). The ROC curve demonstrated that PDE5 serum levels can predict men with or without PCa, with 0.806 AUC value (p < 0.0001). Using a 12.705 ng/ml PDE5 serum cut-off yielded sensitivity, specificity, PPV, and NPV of 83.3%, 77.27%, 62.5%, and 91.1% in detecting men with histologically proven PCa, respectively.

Conclusions: We demonstrated, for the first time, that PDE5 levels can be detected in human sera and that PCa patients have significantly higher PDE5 concentration compared to BPH patients or male and female controls. While serum PDE5 level measurement may open new research avenues, the clinical relevance of PDE5 levels in PCa patients deserves further investigation.

目的:我们的目的是研究能否在人体血清中检测和定量 5 型磷酸二酯酶(PDE5):方法:采集对照组男女受试者的血样。方法:采集对照组男性和女性受试者的血样,用特定的酶联免疫吸附试剂盒检测 PDE5 的水平。采用年龄和血清中 PSA(男性受试者)或年龄(女性受试者)水平加权的 ROC 曲线来确定检测 PCa 的预测能力。根据 ROC 曲线分析中确定的临界值,确定敏感性、特异性、PPV 和 NPV 值:研究对象包括41名对照组男性受试者、18名对照组女性受试者和55名连续受试者,其中25人患有良性前列腺肥大(BPH),30人经组织学证实患有前列腺癌(PCa)。所有受试者的血清中均可检测到 PDE5 水平(范围:5 至 65 纳克/毫升)。通过 MANCOVA 分析发现,对照组或增生患者与 PCa 患者的血清 PDE5 存在显著差异。血清 PDE5 浓度的边际均值显示出显著差异(p 结论:PDE5 浓度的边际均值与 PCa 患者血清 PDE5 浓度的边际均值存在显著差异:我们首次证明,人体血清中可检测到 PDE5 水平,而且 PCa 患者的 PDE5 浓度明显高于良性前列腺增生患者或男女对照组。虽然血清中 PDE5 水平的测量可能会开辟新的研究途径,但 PCa 患者体内 PDE5 水平的临床意义值得进一步研究。
{"title":"Measurement of PDE5 concentration in human serum: proof-of-concept and validation of methodology in control and prostate cancer patients.","authors":"Giovanni Luca Gravina, Eugenia Guida, Maria Dri, Renato Massoud, Savino M Di Stasi, Giorgio Fucci, Andrea Sansone, Susanna Dolci, Emmanuele A Jannini","doi":"10.1007/s40618-024-02428-w","DOIUrl":"https://doi.org/10.1007/s40618-024-02428-w","url":null,"abstract":"<p><strong>Purpose: </strong>We aimed to investigate if the type 5 phosphodiesterase (PDE5), an enzyme with cardinal biological functions in sexual and cardiovascular health, can be detected and quantited in human serum.</p><p><strong>Methods: </strong>Blood samples were collected from control male and female subjects. PDE5 levels were measured by a specific ELISA kit. ROC curves weighted for age and serum levels of PSA (male subjects), or age (female subjects) were used to identify the predictive ability in the detection of PCa. Sensitivity, specificity, PPV and NPV values were determined for cut-off value determined during ROC curve analysis.</p><p><strong>Results: </strong>41 control male subjects, 18 control female subjects, and 55 consecutive subjects, of which 25 were affected by benign prostatic hypertrophy (BPH) and 30 with histologically confirmed prostate cancer (PCa), were studied. PDE5 serum levels were detectable in all subjects (range: 5 to 65 ng/ml). Analysis by MANCOVA identified a significant difference in serum PDE5 between control subjects or hyperplasia patients and PCa patients. Marginal means of serum PDE5 concentrations showed a significant difference (p < 0.001). The ROC curve demonstrated that PDE5 serum levels can predict men with or without PCa, with 0.806 AUC value (p < 0.0001). Using a 12.705 ng/ml PDE5 serum cut-off yielded sensitivity, specificity, PPV, and NPV of 83.3%, 77.27%, 62.5%, and 91.1% in detecting men with histologically proven PCa, respectively.</p><p><strong>Conclusions: </strong>We demonstrated, for the first time, that PDE5 levels can be detected in human sera and that PCa patients have significantly higher PDE5 concentration compared to BPH patients or male and female controls. While serum PDE5 level measurement may open new research avenues, the clinical relevance of PDE5 levels in PCa patients deserves further investigation.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142330487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Who and how to screen for endogenous hypercortisolism in a high-risk population: a special issue of the journal of endocrinological investigations. 在高危人群中筛查内源性皮质醇过多症的对象和方法:《内分泌学调查》杂志特刊。
IF 5.4 2区 医学 Q1 Medicine Pub Date : 2024-10-01 DOI: 10.1007/s40618-024-02449-5
Filippo Ceccato, Massimo Terzolo, Carla Scaroni
{"title":"Who and how to screen for endogenous hypercortisolism in a high-risk population: a special issue of the journal of endocrinological investigations.","authors":"Filippo Ceccato, Massimo Terzolo, Carla Scaroni","doi":"10.1007/s40618-024-02449-5","DOIUrl":"https://doi.org/10.1007/s40618-024-02449-5","url":null,"abstract":"","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142330491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unusual infections and thrombotic events in Cushing's syndrome. 库欣综合征的异常感染和血栓事件。
IF 5.4 2区 医学 Q1 Medicine Pub Date : 2024-10-01 DOI: 10.1007/s40618-024-02454-8
Mattia Barbot, Martina Lazzara, Pierluigi Mazzeo, Francesca Pecori Giraldi

The diagnosis of Cushing's syndrome requires a high degree of suspicion, especially in patients in whom typical features are overshadowed by other ailments. These include, among others, widespread opportunistic infections or sepsis and venous or arterial thromboembolism.This Review will summarize available data on patients presenting with severe infections or thrombotic events and the best approach to diagnosis.

库欣综合征的诊断需要高度怀疑,尤其是那些被其他疾病掩盖了典型特征的患者。本综述将总结出现严重感染或血栓事件的患者的现有数据以及最佳诊断方法。
{"title":"Unusual infections and thrombotic events in Cushing's syndrome.","authors":"Mattia Barbot, Martina Lazzara, Pierluigi Mazzeo, Francesca Pecori Giraldi","doi":"10.1007/s40618-024-02454-8","DOIUrl":"10.1007/s40618-024-02454-8","url":null,"abstract":"<p><p>The diagnosis of Cushing's syndrome requires a high degree of suspicion, especially in patients in whom typical features are overshadowed by other ailments. These include, among others, widespread opportunistic infections or sepsis and venous or arterial thromboembolism.This Review will summarize available data on patients presenting with severe infections or thrombotic events and the best approach to diagnosis.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142330490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ACROMORFO study: gait analysis in a cohort of acromegalic patients. ACROMORFO 研究:一组肢端肥大症患者的步态分析。
IF 5.4 2区 医学 Q1 Medicine Pub Date : 2024-10-01 Epub Date: 2024-02-28 DOI: 10.1007/s40618-024-02340-3
V Cimolin, C Premoli, G Bernardelli, E Amenta, M Galli, L Donno, D Lucini, L M Fatti, B Cangiano, L Persani, G Vitale

Purpose: In acromegaly, skeletal complications resulted to be associated with low quality of life (QoL) and high risk of falls. The aim of the present study was to perform a quantitative assessment of movement through gait analysis technique in patients with acromegaly.

Study population: Thirty-three acromegalic patients [9 with active disease (AD), 14 with controlled disease (CD) and 10 with disease remission (RD)] and 20 healthy subjects were enrolled for the study.

Measurements: Kinetic and kinematic data were collected with 3D-gait analysis. Kinematic data were processed to compute the Gait Profile Score (GPS), a parameter that summarizes the overall deviation of kinematic gait data relative to unaffected population.

Results: The acromegalic group showed longer stance phase duration (p < 0.0001) compared to controls. The GPS and several gait variable scores resulted to be statistically higher in the acromegalic group compared to healthy controls. GPS values were significantly higher in AD compared to CD (p < 0.05) and RD groups (p = 0.001). The AD group presented significantly higher values in terms of hip rotation and ankle dorsiflexion compared to CD and RD groups and with regard to the foot progression compared to RD. Interestingly, patients with RD exhibited a more physiological gait pattern.

Conclusion: Acromegalic patients showed quantitative alterations of gait pattern, suggesting instability and increased risk of falls. Arthropathy, along with its associated abnormal joint loading, proprioceptive impairment and hyperkyphosis could be contributing factors. Disease control and remission appear to improve postural balance. A better knowledge on walking performance in acromegaly would help to develop specific rehabilitation programmes to reduce falls' risk and improve QoL.

目的:肢端肥大症患者的骨骼并发症与低生活质量(QoL)和高跌倒风险有关。本研究旨在通过步态分析技术对肢端肥大症患者的运动情况进行定量评估:研究对象:33 名肢端肥大症患者(9 名活动期患者(AD)、14 名控制期患者(CD)和 10 名疾病缓解期患者(RD))和 20 名健康受试者:通过三维步态分析收集动力学和运动学数据。对运动数据进行处理,计算步态轮廓评分(GPS),该参数概括了运动步态数据相对于未受影响人群的总体偏差:肢端肥大症组的步态阶段持续时间更长(p 结论:肢端肥大症组的步态阶段持续时间更长(p):肢端肥大症患者的步态模式发生了定量改变,表明其步态不稳定,跌倒风险增加。关节病及其相关的异常关节负荷、本体感觉障碍和肌张力过高可能是诱因。疾病控制和缓解似乎能改善姿势平衡。如果能更好地了解肢端肥大症患者的行走表现,将有助于制定特定的康复计划,以降低跌倒风险并提高生活质量。
{"title":"ACROMORFO study: gait analysis in a cohort of acromegalic patients.","authors":"V Cimolin, C Premoli, G Bernardelli, E Amenta, M Galli, L Donno, D Lucini, L M Fatti, B Cangiano, L Persani, G Vitale","doi":"10.1007/s40618-024-02340-3","DOIUrl":"10.1007/s40618-024-02340-3","url":null,"abstract":"<p><strong>Purpose: </strong>In acromegaly, skeletal complications resulted to be associated with low quality of life (QoL) and high risk of falls. The aim of the present study was to perform a quantitative assessment of movement through gait analysis technique in patients with acromegaly.</p><p><strong>Study population: </strong>Thirty-three acromegalic patients [9 with active disease (AD), 14 with controlled disease (CD) and 10 with disease remission (RD)] and 20 healthy subjects were enrolled for the study.</p><p><strong>Measurements: </strong>Kinetic and kinematic data were collected with 3D-gait analysis. Kinematic data were processed to compute the Gait Profile Score (GPS), a parameter that summarizes the overall deviation of kinematic gait data relative to unaffected population.</p><p><strong>Results: </strong>The acromegalic group showed longer stance phase duration (p < 0.0001) compared to controls. The GPS and several gait variable scores resulted to be statistically higher in the acromegalic group compared to healthy controls. GPS values were significantly higher in AD compared to CD (p < 0.05) and RD groups (p = 0.001). The AD group presented significantly higher values in terms of hip rotation and ankle dorsiflexion compared to CD and RD groups and with regard to the foot progression compared to RD. Interestingly, patients with RD exhibited a more physiological gait pattern.</p><p><strong>Conclusion: </strong>Acromegalic patients showed quantitative alterations of gait pattern, suggesting instability and increased risk of falls. Arthropathy, along with its associated abnormal joint loading, proprioceptive impairment and hyperkyphosis could be contributing factors. Disease control and remission appear to improve postural balance. A better knowledge on walking performance in acromegaly would help to develop specific rehabilitation programmes to reduce falls' risk and improve QoL.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":"2469-2476"},"PeriodicalIF":5.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11393285/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139984251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rachel score: a nomogram model for predicting the prognosis of lung neuroendocrine tumors. 雷切尔评分:预测肺部神经内分泌肿瘤预后的提名图模型。
IF 5.4 2区 医学 Q1 Medicine Pub Date : 2024-10-01 Epub Date: 2024-03-23 DOI: 10.1007/s40618-024-02346-x
A La Salvia, B Marcozzi, C Manai, R Mazzilli, L Landi, M Pallocca, G Ciliberto, F Cappuzzo, A Faggiano

Background: Lung NET, classified in typical carcinoids (TC) and atypical carcinoids (AC), are highly heterogeneous in their biology and prognosis. The histological subtype and TNM stage are well-established prognostic factors for lung NET. In a previous work by our group, we demonstrated a significant impact of laterality on lung NET survival outcomes.

Materials and methods: We developed a nomogram that integrates relevant prognostic factors to predict lung NET outcomes. By adding the scores for each of the variables included in the model, it was possible to obtain a prognostic score (Rachel score). Wilcoxon non-parametric statistical test was applied among parameters and Harrell's concordance index was used to measure the models' predictive power. To test the discriminatory power and the predictive accuracy of the model, we calculated Gonen and Heller concordance index. Time-dependent ROC curves and their area under the curve (AUC) were used to evaluate the models' predictive performance.

Results: By applying Rachel score, we were able to identify three prognostic groups (specifically, high, medium and low risk). These three groups were associate to well-defined ranges of points according to the obtained nomogram (I: 0-90, II: 91-130; III: > 130 points), providing a useful tool for prognostic stratification. The overall survival (OS) and progression free survival (PFS) Kaplan-Meier curves confirmed significant differences (p < 0.0001) among the three groups identified by Rachel score.

Conclusions: A prognostic nomogram was developed, incorporating variables with significant impact on lung NET survival. The nomogram showed a satisfactory and stable ability to predict OS and PFS in this population, confirming the heterogeneity beyond the histopathological diagnosis of TC vs AC.

背景:肺癌分为典型类癌(TC)和不典型类癌(AC),其生物学特性和预后具有高度异质性。组织学亚型和 TNM 分期是公认的肺癌预后因素。在我们小组之前的一项工作中,我们证实了侧位对肺NET生存结果的显著影响:我们开发了一种整合了相关预后因素的提名图来预测肺 NET 的预后。通过将模型中每个变量的得分相加,可以得到一个预后评分(Rachel 评分)。各参数之间采用 Wilcoxon 非参数统计检验,并使用 Harrell 一致性指数来衡量模型的预测能力。为了检验模型的鉴别力和预测准确性,我们计算了 Gonen 和 Heller 一致性指数。与时间相关的 ROC 曲线及其曲线下面积(AUC)用于评估模型的预测性能:通过应用 Rachel 评分,我们确定了三个预后组(具体为高、中、低风险)。根据所得到的提名图,这三个组与定义明确的分数范围相关联(I:0-90;II:91-130;III:>130 分),为预后分层提供了有用的工具。总生存期(OS)和无进展生存期(PFS)Kaplan-Meier曲线证实,Rachel评分确定的三个组别之间存在显著差异(P < 0.0001):结论:结合对肺NET生存有重大影响的变量,制定了预后提名图。该提名图在预测该人群的OS和PFS方面显示出令人满意且稳定的能力,证实了组织病理学诊断TC vs AC之外的异质性。
{"title":"Rachel score: a nomogram model for predicting the prognosis of lung neuroendocrine tumors.","authors":"A La Salvia, B Marcozzi, C Manai, R Mazzilli, L Landi, M Pallocca, G Ciliberto, F Cappuzzo, A Faggiano","doi":"10.1007/s40618-024-02346-x","DOIUrl":"10.1007/s40618-024-02346-x","url":null,"abstract":"<p><strong>Background: </strong>Lung NET, classified in typical carcinoids (TC) and atypical carcinoids (AC), are highly heterogeneous in their biology and prognosis. The histological subtype and TNM stage are well-established prognostic factors for lung NET. In a previous work by our group, we demonstrated a significant impact of laterality on lung NET survival outcomes.</p><p><strong>Materials and methods: </strong>We developed a nomogram that integrates relevant prognostic factors to predict lung NET outcomes. By adding the scores for each of the variables included in the model, it was possible to obtain a prognostic score (Rachel score). Wilcoxon non-parametric statistical test was applied among parameters and Harrell's concordance index was used to measure the models' predictive power. To test the discriminatory power and the predictive accuracy of the model, we calculated Gonen and Heller concordance index. Time-dependent ROC curves and their area under the curve (AUC) were used to evaluate the models' predictive performance.</p><p><strong>Results: </strong>By applying Rachel score, we were able to identify three prognostic groups (specifically, high, medium and low risk). These three groups were associate to well-defined ranges of points according to the obtained nomogram (I: 0-90, II: 91-130; III: > 130 points), providing a useful tool for prognostic stratification. The overall survival (OS) and progression free survival (PFS) Kaplan-Meier curves confirmed significant differences (p < 0.0001) among the three groups identified by Rachel score.</p><p><strong>Conclusions: </strong>A prognostic nomogram was developed, incorporating variables with significant impact on lung NET survival. The nomogram showed a satisfactory and stable ability to predict OS and PFS in this population, confirming the heterogeneity beyond the histopathological diagnosis of TC vs AC.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":"2575-2586"},"PeriodicalIF":5.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140194869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of the finasteride treatment and its withdrawal in the rat hypothalamus and hippocampus at whole-transcriptome level. 从全转录组水平分析大鼠下丘脑和海马的非那雄胺治疗和停药情况。
IF 5.4 2区 医学 Q1 Medicine Pub Date : 2024-10-01 Epub Date: 2024-03-17 DOI: 10.1007/s40618-024-02345-y
S Giatti, L Cioffi, S Diviccaro, R Piazza, R C Melcangi

Purpose: As reported in patients treated for androgenetic alopecia with finasteride (i.e., a blocker of the enzyme 5 alpha-reductase) and in an animal model, side effects affecting sexual, psychiatric, neurological, and physical domains, may occur during the treatment and persist with drug suspension. The etiopathogenesis of these side effects has been poorly explored. Therefore, we performed a genome-wide analysis of finasteride effects in the brain of adult male rat.

Methods: Animals were treated (i.e., for 20 days) with finasteride (1mg/rat/day). 24 h after the last treatment and 1 month after drug suspension, RNA sequencing analysis was performed in hypothalamus and hippocampus. Data were analyzed by differential expression analysis and Gene-Set Enrichment Analyses (GSEA).

Results: Data obtained after finasteride treatment showed that 186 genes (i.e., 171 up- and 15 downregulated) and 19 (i.e., 17 up- and 2 downregulated) were differentially expressed in the hypothalamus and hippocampus, respectively. Differential expression analysis at the drug withdrawal failed to identify dysregulated genes. Several gene-sets were enriched in these brain areas at both time points.

Conclusion: Some of the genes reported to be differentially expressed (i.e., TTR, DIO2, CLDN1, CLDN2, SLC4A5, KCNE2, CROT, HCRT, MARCKSL1, VGF, IRF2BPL) and GSEA, suggest a potential link with specific side effects previously observed in patients and in the animal model, such as depression, anxiety, disturbance in memory and attention, and sleep disturbance. These data may provide an important background for future experiments aimed at confirming the pathological role of these genes.

目的:据报道,在使用非那雄胺(即 5 α-还原酶的阻断剂)治疗雄激素性脱发的患者中以及在动物模型中,可能会在治疗期间出现影响性、精神、神经和身体领域的副作用,并且在停药后仍会持续。对这些副作用的病因尚未进行深入研究。因此,我们对非那雄胺对成年雄性大鼠大脑的影响进行了全基因组分析:方法:用非那雄胺(1 毫克/只/天)对动物进行治疗(即 20 天)。在最后一次治疗 24 小时后和停药 1 个月后,对下丘脑和海马进行 RNA 测序分析。数据通过差异表达分析和基因组富集分析(Gene-Set Enrichment Analyses,GSEA)进行分析:结果:非那雄胺治疗后获得的数据显示,186个基因(即171个上调,15个下调)和19个基因(即17个上调,2个下调)分别在下丘脑和海马中差异表达。停药时的差异表达分析未能发现失调基因。在这两个时间点,这些脑区都富集了几个基因集:结论:报告的一些差异表达基因(即 TTR、DIO2、CLDN1、CLDN2、SLC4A5、KCNE2、CROT、HCRT、MARCKSL1、VGF、IRF2BPL)和 GSEA 表明,这些基因与之前在患者和动物模型中观察到的特定副作用(如抑郁、焦虑、记忆和注意力障碍以及睡眠障碍)存在潜在联系。这些数据可为今后旨在证实这些基因的病理作用的实验提供重要背景。
{"title":"Analysis of the finasteride treatment and its withdrawal in the rat hypothalamus and hippocampus at whole-transcriptome level.","authors":"S Giatti, L Cioffi, S Diviccaro, R Piazza, R C Melcangi","doi":"10.1007/s40618-024-02345-y","DOIUrl":"10.1007/s40618-024-02345-y","url":null,"abstract":"<p><strong>Purpose: </strong>As reported in patients treated for androgenetic alopecia with finasteride (i.e., a blocker of the enzyme 5 alpha-reductase) and in an animal model, side effects affecting sexual, psychiatric, neurological, and physical domains, may occur during the treatment and persist with drug suspension. The etiopathogenesis of these side effects has been poorly explored. Therefore, we performed a genome-wide analysis of finasteride effects in the brain of adult male rat.</p><p><strong>Methods: </strong>Animals were treated (i.e., for 20 days) with finasteride (1mg/rat/day). 24 h after the last treatment and 1 month after drug suspension, RNA sequencing analysis was performed in hypothalamus and hippocampus. Data were analyzed by differential expression analysis and Gene-Set Enrichment Analyses (GSEA).</p><p><strong>Results: </strong>Data obtained after finasteride treatment showed that 186 genes (i.e., 171 up- and 15 downregulated) and 19 (i.e., 17 up- and 2 downregulated) were differentially expressed in the hypothalamus and hippocampus, respectively. Differential expression analysis at the drug withdrawal failed to identify dysregulated genes. Several gene-sets were enriched in these brain areas at both time points.</p><p><strong>Conclusion: </strong>Some of the genes reported to be differentially expressed (i.e., TTR, DIO2, CLDN1, CLDN2, SLC4A5, KCNE2, CROT, HCRT, MARCKSL1, VGF, IRF2BPL) and GSEA, suggest a potential link with specific side effects previously observed in patients and in the animal model, such as depression, anxiety, disturbance in memory and attention, and sleep disturbance. These data may provide an important background for future experiments aimed at confirming the pathological role of these genes.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":"2565-2574"},"PeriodicalIF":5.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11393021/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140140933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The need for the GREAT+ score to predict relapse in Graves' disease: a questionnaire among patients and internal medicine specialists. 用 GREAT+ 评分预测巴塞杜氏病复发的必要性:患者和内科专家问卷调查。
IF 5.4 2区 医学 Q1 Medicine Pub Date : 2024-10-01 Epub Date: 2024-03-25 DOI: 10.1007/s40618-024-02358-7
H I Jansen, C Heuveling van Beek, P H Bisschop, A C Heijboer, E Bruinstroop, A Boelen

Purpose: Graves' disease (GD) is an auto-immune cause of hyperthyroidism. First-line treatment often consists of a 12-18 month course of antithyroid drugs (ATD). After discontinuation of ATD, GD relapses in approximately 50% of patients. The 'Graves recurrent event after therapy+ ' (GREAT+) score may predict individual relapse chances after ATD discontinuation more accurately based on clinical and laboratory parameters at diagnosis. We investigated the need for the GREAT+ score through an online questionnaire among GD patients and physicians treating GD.

Methods: An anonymous online questionnaire was distributed to patients and physicians between June 2022 and August 2023.

Results: The questionnaire was completed by 532 patients and 44 physicians. Results showed that 94% of patients were interested in knowing their GREAT+ score at the start of treatment. 55% would consider definite treatment (radioiodine/thyroidectomy) as first-line treatment in case of a high relapse chance. 98% of the physicians indicated the GREAT + score would support patient counseling. 84% may change their advice for first-line treatment if a patient has a high relapse chance based on the score.

Conclusion: Patients and physicians considered the GREAT+ score as a valuable addition to the current available information which could change treatment decisions. Therefore, external validation of the GREAT+ score is justified to implement this score in clinical practice.

目的:巴塞杜氏病(GD)是导致甲状腺功能亢进的自身免疫性疾病。一线治疗通常包括为期12-18个月的抗甲状腺药物(ATD)疗程。停用抗甲状腺药物后,约有50%的患者会复发。根据诊断时的临床和实验室参数,"治疗后巴塞杜氏复发事件+"(GREAT+)评分可以更准确地预测停用ATD后的复发几率。我们通过在线问卷调查了 GD 患者和治疗 GD 的医生对 GREAT+ 评分的需求:方法:我们在 2022 年 6 月至 2023 年 8 月期间向患者和医生发放了一份匿名在线问卷:共有 532 名患者和 44 名医生填写了问卷。结果显示,94% 的患者有兴趣在治疗开始时了解自己的 GREAT+ 分数。55%的患者在复发几率较高的情况下会考虑将明确治疗(放射性碘/甲状腺切除术)作为一线治疗。98% 的医生表示,GREAT + 分数将有助于为患者提供咨询。如果患者的复发几率很高,84%的医生可能会根据评分改变他们的一线治疗建议:患者和医生认为 GREAT+ 评分是对现有信息的宝贵补充,可改变治疗决策。因此,有必要对 GREAT+ 评分进行外部验证,以便在临床实践中使用该评分。
{"title":"The need for the GREAT+ score to predict relapse in Graves' disease: a questionnaire among patients and internal medicine specialists.","authors":"H I Jansen, C Heuveling van Beek, P H Bisschop, A C Heijboer, E Bruinstroop, A Boelen","doi":"10.1007/s40618-024-02358-7","DOIUrl":"10.1007/s40618-024-02358-7","url":null,"abstract":"<p><strong>Purpose: </strong>Graves' disease (GD) is an auto-immune cause of hyperthyroidism. First-line treatment often consists of a 12-18 month course of antithyroid drugs (ATD). After discontinuation of ATD, GD relapses in approximately 50% of patients. The 'Graves recurrent event after therapy+ ' (GREAT+) score may predict individual relapse chances after ATD discontinuation more accurately based on clinical and laboratory parameters at diagnosis. We investigated the need for the GREAT+ score through an online questionnaire among GD patients and physicians treating GD.</p><p><strong>Methods: </strong>An anonymous online questionnaire was distributed to patients and physicians between June 2022 and August 2023.</p><p><strong>Results: </strong>The questionnaire was completed by 532 patients and 44 physicians. Results showed that 94% of patients were interested in knowing their GREAT+ score at the start of treatment. 55% would consider definite treatment (radioiodine/thyroidectomy) as first-line treatment in case of a high relapse chance. 98% of the physicians indicated the GREAT + score would support patient counseling. 84% may change their advice for first-line treatment if a patient has a high relapse chance based on the score.</p><p><strong>Conclusion: </strong>Patients and physicians considered the GREAT+ score as a valuable addition to the current available information which could change treatment decisions. Therefore, external validation of the GREAT+ score is justified to implement this score in clinical practice.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":"2499-2505"},"PeriodicalIF":5.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11393202/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140289356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thymic hyperplasia is accurate to detect new-onset Graves' hyperthyroidism and resolves after restoring euthyroidism. 胸腺增生可准确检测出新发的巴塞杜氏甲亢,并在恢复甲状腺功能正常后消退。
IF 5.4 2区 医学 Q1 Medicine Pub Date : 2024-10-01 Epub Date: 2024-03-30 DOI: 10.1007/s40618-024-02355-w
L Scappaticcio, P Caruso, N Di Martino, P Ferrazzano, A Clemente, M I Maiorino, A Regginelli, G Docimo, P F Rambaldi, G Bellastella, P Trimboli, S Cappabianca, K Esposito

Purpose: Abnormal liver blood tests (ALBTs), neutropenia (NEU) and thymic hyperplasia (TH) are new features of Graves' disease (GD). Our objectives were: (a) to calculate the accuracy of TH in discriminating between Graves' and non-Graves' thyrotoxicosis, compared to ALBTs, NEU and Graves' orbitopathy (GO); (b) to explore the outcome of GD-associated TH and non-GD-associated TH.

Methods: We prospectively analyzed consecutive adult patients with newly diagnosed thyrotoxicosis from January 2018 to June 2023. TH was detected via neck ultrasound (nUS) then confirmed and followed by magnetic resonance imaging (MRI). For GD vs non-GD clinical sensitivity (SE) and specificity (SPEC), accuracy, positive predictive value (PPV) and negative predictive value (NPV) of GO, TH, ALBTs and NEU were calculated.

Results: 264 thyrotoxic patients were included. TH was found in 16.4% (20/122) of GD vs 1.4% (2/142) in non-GD (p < 0.001). SE, SPEC, accuracy, PPV and NPV of the four extrathyroidal manifestations of GD were as follows, respectively: GO 26%, 100%, 66%, 100%, 61%; ALBTs 41%, 89%, 69%, 76%, 66%; NEU 5%, 100%, 56%, 100%, 55%; TH 16%, 98%, 61%, 91%, 98%. In 18 of them, TH regressed within 12 months after achieving euthyroidism under anti-thyroid drug therapy, while in the remaining 2, TH regressed 6 months after thyroid surgery. In the two non-GD patients with TH, thymus disappeared along with euthyroidism.

Conclusions: TH in the hyperthyroidism scenario provides a high PPV for GD. A conservative approach for the diagnostic work-up and initial management of thyrotoxicosis-associated TH should be adopted.

目的:肝脏血液化验(ALBT)异常、中性粒细胞减少症(NEU)和胸腺增生(TH)是巴塞杜氏病(GD)的新特征。我们的目标是(a)与ALBTs、NEU和巴塞杜氏眶病(GO)相比,计算胸腺增生在区分巴塞杜氏病和非巴塞杜氏病甲状腺毒症方面的准确性;(b)探讨GD相关性胸腺增生和非GD相关性胸腺增生的结局:我们对2018年1月至2023年6月期间新确诊的甲亢成年患者进行了前瞻性分析。TH通过颈部超声(nUS)检测,然后通过磁共振成像(MRI)确认和跟踪。计算了GD与非GD的临床敏感性(SE)和特异性(SPEC)、准确性、GO、TH、ALBTs和NEU的阳性预测值(PPV)和阴性预测值(NPV)。16.4%的 GD 患者(20/122)与 1.4%的非 GD 患者(2/142)发现了 TH(P 结论:GD 和非 GD 患者中均未发现 TH:甲状腺功能亢进情况下的 TH 可为 GD 提供较高的 PPV。对于甲亢相关的TH,应采取保守的诊断和初始治疗方法。
{"title":"Thymic hyperplasia is accurate to detect new-onset Graves' hyperthyroidism and resolves after restoring euthyroidism.","authors":"L Scappaticcio, P Caruso, N Di Martino, P Ferrazzano, A Clemente, M I Maiorino, A Regginelli, G Docimo, P F Rambaldi, G Bellastella, P Trimboli, S Cappabianca, K Esposito","doi":"10.1007/s40618-024-02355-w","DOIUrl":"10.1007/s40618-024-02355-w","url":null,"abstract":"<p><strong>Purpose: </strong>Abnormal liver blood tests (ALBTs), neutropenia (NEU) and thymic hyperplasia (TH) are new features of Graves' disease (GD). Our objectives were: (a) to calculate the accuracy of TH in discriminating between Graves' and non-Graves' thyrotoxicosis, compared to ALBTs, NEU and Graves' orbitopathy (GO); (b) to explore the outcome of GD-associated TH and non-GD-associated TH.</p><p><strong>Methods: </strong>We prospectively analyzed consecutive adult patients with newly diagnosed thyrotoxicosis from January 2018 to June 2023. TH was detected via neck ultrasound (nUS) then confirmed and followed by magnetic resonance imaging (MRI). For GD vs non-GD clinical sensitivity (SE) and specificity (SPEC), accuracy, positive predictive value (PPV) and negative predictive value (NPV) of GO, TH, ALBTs and NEU were calculated.</p><p><strong>Results: </strong>264 thyrotoxic patients were included. TH was found in 16.4% (20/122) of GD vs 1.4% (2/142) in non-GD (p < 0.001). SE, SPEC, accuracy, PPV and NPV of the four extrathyroidal manifestations of GD were as follows, respectively: GO 26%, 100%, 66%, 100%, 61%; ALBTs 41%, 89%, 69%, 76%, 66%; NEU 5%, 100%, 56%, 100%, 55%; TH 16%, 98%, 61%, 91%, 98%. In 18 of them, TH regressed within 12 months after achieving euthyroidism under anti-thyroid drug therapy, while in the remaining 2, TH regressed 6 months after thyroid surgery. In the two non-GD patients with TH, thymus disappeared along with euthyroidism.</p><p><strong>Conclusions: </strong>TH in the hyperthyroidism scenario provides a high PPV for GD. A conservative approach for the diagnostic work-up and initial management of thyrotoxicosis-associated TH should be adopted.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":"2487-2497"},"PeriodicalIF":5.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11393051/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140327239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sculptures with goiter in the Ossuccio Sacred Mount: when pathognomonic signs have a specific moral significance. 奥苏奇奥圣山中的甲状腺肿大雕塑:当病兆具有特定的道德意义时。
IF 5.4 2区 医学 Q1 Medicine Pub Date : 2024-10-01 Epub Date: 2024-06-26 DOI: 10.1007/s40618-024-02423-1
G Zavagli, V Marino Picciola, P Zamboni
{"title":"Sculptures with goiter in the Ossuccio Sacred Mount: when pathognomonic signs have a specific moral significance.","authors":"G Zavagli, V Marino Picciola, P Zamboni","doi":"10.1007/s40618-024-02423-1","DOIUrl":"10.1007/s40618-024-02423-1","url":null,"abstract":"","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":"2623-2625"},"PeriodicalIF":5.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141451998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of TMEM163 protein in thyroid microcarcinoma: expression pattern and clinical implications. TMEM163蛋白在甲状腺微癌中的作用:表达模式和临床意义。
IF 5.4 2区 医学 Q1 Medicine Pub Date : 2024-10-01 DOI: 10.1007/s40618-024-02434-y
Ye Wang, Jiafu Li, Shichun Gao, Dejing Dang, Yanlin Chen, Zhiyu Li, Hong Yang

Background: TMEM163 protein is a new zinc ion transporter whose regulatory role in tumors has yet to be discovered. This study aimed to analyze the expression pattern of TMEM163 in thyroid microcarcinoma and explore its potential molecular function and clinical value.

Methods: Differential analysis was performed to detect the expression pattern of TMEM163 in papillary thyroid carcinoma. Functional analysis was performed to explore the biological function of TMEM163. Logistic regression was performed to detect the relationship between TMEM163 expression and lymph node metastasis. A correlation analysis of the relationship between 163 and anoikis was performed. qRT-PCR and western blot were used to verify its expression in PTC tissues. The effect of TMEM163 on PTC cell function was studied by a series of in vitro cell experiments. The prediction model of lymph node metastasis was constructed based on the ultrasonic characteristics of PTMC and the expression of TMEM163.

Results: The expression of TMEM163 in PTC tissue was higher than in normal thyroid tissue. In vitro, silencing TMEM163 inhibited PTC cells' proliferation, migration, and invasion, while TMEM163 overexpression exhibited the opposite effect. In addition, down-regulating its expression can inhibit the cell cycle process and induce the apoptosis of tumor cells. In pathway analysis, we demonstrated that knockout of TMEM163 significantly increased p21 expression and inhibited BCL-2 expression. Logistic regression results suggested that the expression of TMEM163 combined with PTMC ultrasound characteristics helped predict lymph node metastasis.

Conclusion: TMEM163 is highly expressed in PTC, which may be involved in the mechanism of anoikis, and can be used as a molecular marker to predict PTMC lymph node metastasis.

背景:TMEM163蛋白是一种新的锌离子转运体,其在肿瘤中的调控作用尚未被发现。本研究旨在分析TMEM163在甲状腺微癌中的表达模式,并探讨其潜在的分子功能和临床价值:方法:通过差异分析检测TMEM163在甲状腺乳头状癌中的表达模式。方法:通过差异分析检测TMEM163在甲状腺乳头状癌中的表达模式。通过逻辑回归检测TMEM163表达与淋巴结转移之间的关系。采用qRT-PCR和Western blot验证了TMEM163在PTC组织中的表达。通过一系列体外细胞实验研究了 TMEM163 对 PTC 细胞功能的影响。根据PTMC的超声特征和TMEM163的表达构建了淋巴结转移预测模型:结果:TMEM163在PTC组织中的表达高于正常甲状腺组织。在体外,沉默 TMEM163 可抑制 PTC 细胞的增殖、迁移和侵袭,而过表达 TMEM163 则表现出相反的效果。此外,下调其表达可抑制细胞周期过程并诱导肿瘤细胞凋亡。在通路分析中,我们发现敲除 TMEM163 会显著增加 p21 的表达,抑制 BCL-2 的表达。逻辑回归结果表明,TMEM163的表达结合PTMC超声特征有助于预测淋巴结转移:结论:TMEM163在PTC中高表达,可能参与厌氧机制,可作为预测PTMC淋巴结转移的分子标记物。
{"title":"The role of TMEM163 protein in thyroid microcarcinoma: expression pattern and clinical implications.","authors":"Ye Wang, Jiafu Li, Shichun Gao, Dejing Dang, Yanlin Chen, Zhiyu Li, Hong Yang","doi":"10.1007/s40618-024-02434-y","DOIUrl":"https://doi.org/10.1007/s40618-024-02434-y","url":null,"abstract":"<p><strong>Background: </strong>TMEM163 protein is a new zinc ion transporter whose regulatory role in tumors has yet to be discovered. This study aimed to analyze the expression pattern of TMEM163 in thyroid microcarcinoma and explore its potential molecular function and clinical value.</p><p><strong>Methods: </strong>Differential analysis was performed to detect the expression pattern of TMEM163 in papillary thyroid carcinoma. Functional analysis was performed to explore the biological function of TMEM163. Logistic regression was performed to detect the relationship between TMEM163 expression and lymph node metastasis. A correlation analysis of the relationship between 163 and anoikis was performed. qRT-PCR and western blot were used to verify its expression in PTC tissues. The effect of TMEM163 on PTC cell function was studied by a series of in vitro cell experiments. The prediction model of lymph node metastasis was constructed based on the ultrasonic characteristics of PTMC and the expression of TMEM163.</p><p><strong>Results: </strong>The expression of TMEM163 in PTC tissue was higher than in normal thyroid tissue. In vitro, silencing TMEM163 inhibited PTC cells' proliferation, migration, and invasion, while TMEM163 overexpression exhibited the opposite effect. In addition, down-regulating its expression can inhibit the cell cycle process and induce the apoptosis of tumor cells. In pathway analysis, we demonstrated that knockout of TMEM163 significantly increased p21 expression and inhibited BCL-2 expression. Logistic regression results suggested that the expression of TMEM163 combined with PTMC ultrasound characteristics helped predict lymph node metastasis.</p><p><strong>Conclusion: </strong>TMEM163 is highly expressed in PTC, which may be involved in the mechanism of anoikis, and can be used as a molecular marker to predict PTMC lymph node metastasis.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142330489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Endocrinological Investigation
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1